None of us have, except in the imagination of the anti EU posters.
.
Brexit, for once some facts.
- Thread starter flecc
- Start date
.
you are confused again.
I copied and pasted numbers that I found on the internet.
The knowledge/expertise isn't mine, I understand what the numbers mean - that's all.
I have never said it wasn't! simply reported ongoing results, you made the rest of what you imagined was my opinion to fit your agenda.
Why don't you want to be aware of the research being carried out?
They have discovered that in some cases extending the interval fails to give good results: we need to be aware of that and not bury our heads in the sand
I (under normal circumstances) live in france/Italy much of the year. I think you are discounting the uk's overall performance over the pandemic. Which may be a mistake. We are most definitely not out of the woods yet and theres some solid reasons (around lack of governance) as to why we have higher death rates than europe from covid.
Stop attacking well meaning people posting reasonably and have a look at the real enemies instead.
Such as Chainring's thread also in the Charging Post, in particular look at the comments from all the POLLY types that are under the video, believing the vaccines are a dangerous government scam designed to harm us.
LINK
.
Last edited:
That document says: "Hold the syringe the way you would a pencil. "
Given some of the bizarre ways I've seen people grasp writing implements, that is a questionable description.
Not being a finance guy, I am not sure of the significance of this , ... But I suspect it reduces economic activity in solicitors offices .. I did have a few shares with Eircom, back in the day, and they eventually went into Vodafone, and then CREST gave me a tiny lump sum. Since it was only 300 quid to start off with,I wasn't a big loser.
From RTE...
"Securities settlement for Irish assets worth over €100 billion has left London for the European Union in the latest adjustment in markets to Brexit
Pan-European exchange Euronext, which runs the Irish stock exchange, said it had completed the migration of securities settlement for 50 Irish companies from Crest in London to Euroclear Bank in Brussels from March 15.
Settlement of EU securities must take place in a central securities depository (CSD) inside the bloc.
While the transfer does not have immediate implications for jobs and tax revenues in Britain, it is a further sign of how its financial services industry is being cut off from the EU.
The EU had given Crest temporary permission to continue settling Irish securities in London until the migration was completed. Crest is part of the Euroclear group.
The migration follows shifts in euro stock and derivatives trading from London to the bloc, with Brussels now targetting the clearing of derivatives.
From RTE...
"Securities settlement for Irish assets worth over €100 billion has left London for the European Union in the latest adjustment in markets to Brexit
Pan-European exchange Euronext, which runs the Irish stock exchange, said it had completed the migration of securities settlement for 50 Irish companies from Crest in London to Euroclear Bank in Brussels from March 15.
Settlement of EU securities must take place in a central securities depository (CSD) inside the bloc.
While the transfer does not have immediate implications for jobs and tax revenues in Britain, it is a further sign of how its financial services industry is being cut off from the EU.
The EU had given Crest temporary permission to continue settling Irish securities in London until the migration was completed. Crest is part of the Euroclear group.
The migration follows shifts in euro stock and derivatives trading from London to the bloc, with Brussels now targetting the clearing of derivatives.
This is a fuller section from the EMAs document... Of Yesterday, . In essence it gives the answer as to why the EMA acted as they did. Note that the initial concerns raised in Austria on 9 th March, where there was a death and a few CVT serous non fatalities, was assumed batch QC related ..from a batch which made 1M doses.
EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. The Committee confirmed that:
The PRAC involved experts in blood disorders in its review, and worked closely with other health authorities including the UK’s MHRA which has experience with administration of this vaccine to around 11 million people. Overall the number of thromboembolic events reported after vaccination, both in studies before licensing and in reports after rollout of vaccination campaigns (469 reports, 191 of them from the EEA), was lower than that expected in the general population. This allows the PRAC to confirm that there is no increase in overall risk of blood clots. However, in younger patients there remain some concerns, related in particular to these rare cases.
The Committee’s experts looked in extreme detail at records of DIC and CVST reported from Member States, 9 of which resulted in death. Most of these occurred in people under 55 and the majority were women. Because these events are rare, and COVID-19 itself often causes blood clotting disorders in patients, it is difficult to estimate a background rate for these events in people who have not had the vaccine. However, based on pre-COVID figures it was calculated that less than 1 reported case of DIC might have been expected by 16 March among people under 50 within 14 days of receiving the vaccine, whereas 5 cases had been reported. Similarly, on average 1.35 cases of CVST might have been expected among this age group whereas by the same cut-off date there had been 12. A similar imbalance was not visible in the older population given the vaccine.
The Committee was of the opinion that the vaccine’s proven efficacy in preventing hospitalisation and death from COVID-19 outweighs the extremely small likelihood of developing DIC or CVST. However, in the light of its findings, patients should be aware of the remote possibility of such syndromes, and if symptoms suggestive of clotting problems occur patients should seek immediate medical attention and inform healthcare professionals of their recent vaccination. Steps are already being taken to update the product information for the vaccine to include more information on these risks.
The PRAC will undertake additional review of these risks, including looking at the risks with other types of COVID-19 vaccines (although no signal has been identified from monitoring so far). Close safety monitoring of reports of blood clotting disorders will continue, and further studies are being instituted to provide more laboratory data as well as real-world evidence. EMA will communicate further as appropriate.
EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. The Committee confirmed that:
- the benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal) continue to outweigh the risk of side effects;
- the vaccine is not associated with an increase in the overall risk of blood clots (thromboembolic events) in those who receive it;
- there is no evidence of a problem related to specific batches of the vaccine or to particular manufacturing sites;
- however, the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, i.e. low levels of blood platelets (elements in the blood that help it to clot) with or without bleeding, including rare cases of clots in the vessels draining blood from the brain (CVST).
The PRAC involved experts in blood disorders in its review, and worked closely with other health authorities including the UK’s MHRA which has experience with administration of this vaccine to around 11 million people. Overall the number of thromboembolic events reported after vaccination, both in studies before licensing and in reports after rollout of vaccination campaigns (469 reports, 191 of them from the EEA), was lower than that expected in the general population. This allows the PRAC to confirm that there is no increase in overall risk of blood clots. However, in younger patients there remain some concerns, related in particular to these rare cases.
The Committee’s experts looked in extreme detail at records of DIC and CVST reported from Member States, 9 of which resulted in death. Most of these occurred in people under 55 and the majority were women. Because these events are rare, and COVID-19 itself often causes blood clotting disorders in patients, it is difficult to estimate a background rate for these events in people who have not had the vaccine. However, based on pre-COVID figures it was calculated that less than 1 reported case of DIC might have been expected by 16 March among people under 50 within 14 days of receiving the vaccine, whereas 5 cases had been reported. Similarly, on average 1.35 cases of CVST might have been expected among this age group whereas by the same cut-off date there had been 12. A similar imbalance was not visible in the older population given the vaccine.
The Committee was of the opinion that the vaccine’s proven efficacy in preventing hospitalisation and death from COVID-19 outweighs the extremely small likelihood of developing DIC or CVST. However, in the light of its findings, patients should be aware of the remote possibility of such syndromes, and if symptoms suggestive of clotting problems occur patients should seek immediate medical attention and inform healthcare professionals of their recent vaccination. Steps are already being taken to update the product information for the vaccine to include more information on these risks.
The PRAC will undertake additional review of these risks, including looking at the risks with other types of COVID-19 vaccines (although no signal has been identified from monitoring so far). Close safety monitoring of reports of blood clotting disorders will continue, and further studies are being instituted to provide more laboratory data as well as real-world evidence. EMA will communicate further as appropriate.
Modena have a clause in their sales contract that the purchaser holds a stock back from distribution sufficient to cover the second dose at their stated dosage interval
Common sense for once
Common sense for once
If true this represents a truly immense step forward, let us sincerely hope it works out!
"
COVID-19: Science behind Pfizer-BioNTech vaccine can be used to give people cancer jabs 'within a couple of years', says co-creator
"
COVID-19: Science behind Pfizer-BioNTech vaccine can be used to give people cancer jabs 'within a couple of years', says co-creator
Well I, m glad it's all cleared up over vaccines in EU and France especially.
They are preventing anybody under 55 from having AZ, apparently they are still ignoring EMA and have decided this age group are more likely to have clots, and since the vaccine is quasi effective for over 65s they are concentrating efforts on those between 55 and 65. When interviewed, however, 52% of this age group were going to refuse AZ because it doesn't work,unless you want a blood clot.
What a joke. In mean time Paris is entering stricter lockdown and leaders there saying they don't have enough time for vaccines to slow down this current wave.. What have they done?
Oh, and in mean time 3 Scandinavian countries are, (in name of consistency??) continuing their stance of ignoring all the new data highlighted by Danidl, (that's irony Danidl) ignoring EMA and WHO and continuing their suspension of AZ.
Saying EU vaccine roll out is a shambles is an insult to the word shambles. How on earth can anyone defend this utter nightmare of the vaccine roll out.
Perhaps Danidl can churn out some data showing that AZ vaccine should be suspended by Scandinavian countries, used by others fully and used for age group 55 to 65 in France. There is nothing like EU solidarity is there. I wonder which science they are all following.Obviously quite a range of scientists, all sitting their O levels in a few years.
I don't think even Flecc or Danidl can find anything to justify this broken, inconsistent, fragmented and almost juvenile attempt.
Just remind me Flecc, what purpose exactly does EMA fulfill. Gives advice and every country, even though having agreed to joint approach and procurement, then ignores them to varying extent..
EU couldn't run a raffle.
They are preventing anybody under 55 from having AZ, apparently they are still ignoring EMA and have decided this age group are more likely to have clots, and since the vaccine is quasi effective for over 65s they are concentrating efforts on those between 55 and 65. When interviewed, however, 52% of this age group were going to refuse AZ because it doesn't work,unless you want a blood clot.
What a joke. In mean time Paris is entering stricter lockdown and leaders there saying they don't have enough time for vaccines to slow down this current wave.. What have they done?
Oh, and in mean time 3 Scandinavian countries are, (in name of consistency??) continuing their stance of ignoring all the new data highlighted by Danidl, (that's irony Danidl) ignoring EMA and WHO and continuing their suspension of AZ.
Saying EU vaccine roll out is a shambles is an insult to the word shambles. How on earth can anyone defend this utter nightmare of the vaccine roll out.
Perhaps Danidl can churn out some data showing that AZ vaccine should be suspended by Scandinavian countries, used by others fully and used for age group 55 to 65 in France. There is nothing like EU solidarity is there. I wonder which science they are all following.Obviously quite a range of scientists, all sitting their O levels in a few years.
I don't think even Flecc or Danidl can find anything to justify this broken, inconsistent, fragmented and almost juvenile attempt.
Just remind me Flecc, what purpose exactly does EMA fulfill. Gives advice and every country, even though having agreed to joint approach and procurement, then ignores them to varying extent..
EU couldn't run a raffle.
Last edited: